Platinum complexes and their use

摘要

The invention relates to platinum complexes and their use in biomedical applications, like in vitro and in vivo imaging and cell staining. The present invention provides new materials and their use as imaging agent. The formation of luminescent aggregates can allow a switch of the emission leading to a dynamic label and on the formation of soft assemblies, which, in some cases, are even more emissive than the isolated corresponding species.

主权项

1. A process of using a platinum (II) complex according to one of formulas (I) or (II)comprising a mono- or dinuclear N^N^N-type ligand
wherein Y1, Y2 , Y3 Y4, Y5, Y6, Y7, Y8 and Y9 can be independently either carbon or nitrogen with the proviso if Y1 or Y4 are a nitrogen atom, then R1 or R19 are absent; if Y2 or Y5 are a nitrogen atom, then R2 or R20 are absent; if Y3 or Y6 are a nitrogen atom, then R3 or R21 are absent; if Y7 is a nitrogen atom, then R28 is absent; if Y8 is a nitrogen atom, then R29 is absent; if Y9 is a nitrogen atom, then R30 is absent, and if Y1, Y2, Y3 Y4, Y5, Y6, Y7, Y8 and Y9 represent a carbon R1, R2 , R3, R19, R20, R21, R28, R29, and R30 are selected from the group comprising H, F, Cl, Br, I, CH3, CF3, NO2, OH, tiocyanate, isotiocyanate, —NCO, —CN, CHO, COOH, keto, amine, mono- or di-alkylamino, mono- or diaryl-amino, alkoxy, heteroaryloxy, alkoxycarbonil, acyloxy, acylamino, mercapto, sulfonylamino, cyano, carbamoyl, sulfonylamino, sulfamoyl, sulfinyl, linear or branched, chiral or achiral, from 2 till 18 carbon atom containing any combination of the following groups: CF3, NO2, OH, CHO, COOH, tiocyanate, isotiocyanate, keto, amine, mono- or di-alkylamino, mono- or diaryl-amino, alkoxy, heteroaryloxy, alkoxycarbonil, acyloxy, acylamino, mercapto, sulfonylamino, cyano, carbamoyl, sulfonylamino, sulfamoyl, sulfinyl, aliphatic or alicyclic alkyl, alkenyl, alkynyl, aryl, ester, carboxy, amine, sulfoxide, amide, phosphine or neutral heterocyclic moieties selected from the group comprising ethyl, n-propyl, phosphine, n-Butyl, t-Butyl, iso-Propyl, Hexyl, F(CF2)m(CH2)n— (m=1-10, n=0-4), F(CF2)m(CH2)nC6H4— (m=1-10, n=0-4), O(CH2CH2O)nCH3(n=0-10000), haloalkyl, mono- or, disulfide, natural or synthetic sugar residuals, biotin, phosphonium moiety, aminoacidic residual, antibody,Phenyl, Chlorophenyl, Tolyl, Anisyl, Trifluoromethylphenyl, Benzyl, Fluorenyl, Carbazolyl, Cyclohexyl, Menthyl, Allyl, Hydroxyphenyl, Pentaflurophenyl, Carboxyphenyl, Naphthyl, Pyridyl, Furyl, Bis-(trifluoromethyl)-phenyl, Carbene, N-heterocyclic Carbene, Imidazolyl, Pyridazinyl, Pyrazinyl, Pyrimidyl, Phosphinyl, any aromatic rings fused with the central N-containing esatomic ring, selected from the group comprising and wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12, X13, X14, X15, X16, X17 and X18 are carbon and nitrogen atoms, that independently combine in such a way to have heterocycles selected from the group comprising pyrroles, diazoles, triazoles, tetrazoles, and wherein R4-9, R22-27 or R31-36 are selected from the group of mono- or polyatomic substituents, and wherein the platinum ion is coordinated to a ligand L and/or L′ which is neutral, mono- or multi-either positively or negatively charged to yield a neutral-core complex, wherein the molecule is either fully neutral or either positively or negatively charged as imaging agent comprising the following steps: in vitro or in vivo incubation of cells with the platinum (II) complex and imaging of the platinum (II) complex by fluorescence microscopy.